SCM
PHAT icon

Silverarc Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Silverarc Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200,000
Closed -$2.86M – 95
2023
Q2 		$2.86M Hold
200,000
– – 0.89% 39
2023
Q1 		$1.43M Buy
+200,000
New +$1.76M 0.59% 51

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Silverarc Capital Management's PHAT Position: Q3 2023 in Review

Silverarc Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q3 2023, closing a stake of 200,000 shares — an estimated $2.86M sold.

Silverarc Capital Management first reported a position in PHAT in Q1 2023 and held it in 2 quarters. The position peaked at $2.86M in Q2 2023. 110 funds tracked by Wall St. Rank hold PHAT as of Q3 2023.

  • Silverarc Capital Management reported no remaining Phathom Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 200,000 Phathom Pharmaceuticals shares in Q3 2023, an estimated $2.86M.
  • Silverarc Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Silverarc Capital Management's Phathom Pharmaceuticals position peaked at $2.86M in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.